Insider Selling: Penumbra, Inc. (NYSE:PEN) CAO Sells 501 Shares of Stock

Penumbra, Inc. (NYSE:PEN) CAO Lambert Shiu sold 501 shares of Penumbra stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $282.88, for a total transaction of $141,722.88. Following the transaction, the chief accounting officer now directly owns 32,969 shares in the company, valued at approximately $9,326,270.72. The trade was a 1.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Penumbra Stock Up 0.8 %

PEN opened at $285.91 on Thursday. The company has a fifty day moving average price of $265.94 and a 200-day moving average price of $234.26. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. Penumbra, Inc. has a one year low of $148.00 and a one year high of $310.00. The firm has a market capitalization of $11.01 billion, a P/E ratio of 840.91, a price-to-earnings-growth ratio of 2.83 and a beta of 0.53.

Penumbra (NYSE:PEN) last posted its earnings results on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The business had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million. Equities research analysts expect that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on PEN. Royal Bank of Canada boosted their target price on shares of Penumbra from $285.00 to $313.00 and gave the company an “outperform” rating in a research report on Wednesday, February 19th. Robert W. Baird boosted their price target on shares of Penumbra from $305.00 to $328.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 19th. StockNews.com lowered shares of Penumbra from a “buy” rating to a “hold” rating in a report on Friday, February 28th. Oppenheimer began coverage on shares of Penumbra in a research note on Tuesday, December 17th. They set an “outperform” rating and a $275.00 target price on the stock. Finally, BTIG Research increased their price objective on shares of Penumbra from $232.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Four analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $292.64.

Institutional Investors Weigh In On Penumbra

Hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC lifted its holdings in Penumbra by 2.1% during the third quarter. FMR LLC now owns 5,896,396 shares of the company’s stock valued at $1,145,729,000 after purchasing an additional 121,465 shares in the last quarter. Champlain Investment Partners LLC raised its position in Penumbra by 20.6% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,547,972 shares of the company’s stock valued at $300,786,000 after purchasing an additional 264,122 shares during the last quarter. State Street Corp increased its stake in Penumbra by 0.3% in the 3rd quarter. State Street Corp now owns 1,236,671 shares of the company’s stock valued at $240,298,000 after buying an additional 3,863 shares during the period. RTW Investments LP grew its stake in shares of Penumbra by 8.4% during the 4th quarter. RTW Investments LP now owns 862,450 shares of the company’s stock worth $204,815,000 after purchasing an additional 66,700 shares during the period. Finally, Baillie Gifford & Co. grew its stake in Penumbra by 23.4% in the 4th quarter. Baillie Gifford & Co. now owns 730,233 shares of the company’s stock valued at $173,416,000 after acquiring an additional 138,387 shares during the last quarter. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.